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Abstract
Epilepsy is a chronic disease of the central nervous system characterized by recurrent 
unprovoked seizures. Up to 30% of patients continue to have seizures despite treatment 
with appropriate anticonvulsant medications. The presence of abnormal oscillatory 
events within neural networks is a major feature of epileptogenesis. The endocannabi-
noid system can modulate these oscillatory events and alter neuronal activity making 
the phytocannabinoids found in Cannabis a potential therapeutic option for patients with 
treatment resistant epilepsy. Many in vitro and in vivo studies have demonstrated the 
anticonvulsant effects of several phytocannabinoids including Δ9-tetrahydrocannabinol 
(Δ9-THC) and Cannabidiol (CBD). Several small observational studies demonstrated a 
favorable response to cannabis herbal extracts (CHE) containing high concentrations of 
CBD in children with treatment resistant epilepsy. Two large double blinded clinical trials 
assessing the efficacy of pharmaceutical grade CBD have also been performed in children 
with treatment resistant seizures in Dravet syndrome and Lennox-Gastaut syndrome. 
Both studies demonstrated an improvement in seizure reduction in children taking CBD 
as compared to the placebo groups. To date there is very limited data regarding the use 
of cannabis based products to treat adult patients with treatment resistant epilepsy with 
only one randomized double blinded placebo controlled clinical trial underway.
Keywords: epilepsy, endocannabinoid system, cannabis, tetrhydrocannabinol, 
cannabidiol
1. Introduction
Recently, there has been renewed interest in the use of cannabis in patients with treatment 
resistant epilepsy. This has, in large part, been driven by a public perception that cannabis 
offers a safe and natural alternative to conventional anticonvulsant therapies. However, the 
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phytocannabinoids found in the cannabis plant do offer some very unique anticonvulsant 
pharmacological properties that warrant further exploration.
In this chapter the authors will provide a brief review of epilepsy and epileptogenesis fol-
lowed by a review of how the endocannabinoid system can alter the processes involved in 
the propagation and suppression of epileptic seizures. This is then followed by a review of 
the phytocannabinoids and their anticonvulsant mechanisms of action. Finally, the authors 
provide a historical background on the use of cannabis to treat patients with epilepsy and a 
review of the most recent clinical trials.
2. Epilepsy
Epilepsy is a chronic disease characterized by recurrent unprovoked seizures. It is defined 
as a disease of the brain in which the patient has either (1) two or more unprovoked seizures 
occurring more than 24 hours apart or (2) one unprovoked seizure and a probability of further 
seizures to be greater than 60% [1]. The prevalence of epilepsy worldwide is estimated to be 
between 4 and 10/1000 people with epilepsy accounting for up to 0.5% of the global burden 
of disease [2, 3]. There is significant geographic variation with prevalence rates of epilepsy 
prevalence rates being much higher in the developing world [4].
Most children and adults with epilepsy respond well to anticonvulsant therapy with approxi-
mately 50% of adults and 70% of children becoming seizure free with their first anticonvul-
sant medication [5, 6, 7]. Up to 30% of patients with epilepsy can be considered to be drug 
resistant which is defined by the International League Against Epilepsy as having failed two 
or more appropriate anticonvulsant treatments at an appropriate dosage [8, 9].
In patients who have failed two appropriate anticonvulsants the likelihood of seizure freedom 
with the addition of further anticonvulsant therapies is low. Treatment options for patients 
with drug resistant epilepsy include further trials of anticonvulsants, resective surgery, neu-
ral pathway stimulation with receptive or vagal nerve stimulation and dietary therapies [10]. 
Further trials of anticonvulsants in adults will result in 16% of patients who had failed their 
first two medications becoming seizure free [11]. In pediatric patients while the likelihood of 
achieving remission for 1 year or more with further medication trials is higher at 57%, many 
will continue to have relapses over time [12]. Resective surgery success rates (as defined as 
obtaining Engel Class 1 seizure freedom) in pediatric and adult patients with surgically ame-
nable epileptogenic lesions range from 34 to 90% depending on the nature and extent of the 
lesion [10, 13].
A full review of the processes that result in brain abnormalities causing seizures (epileptogen-
esis) is beyond the scope of this chapter. However, in order to understand how cannabinoids 
can have potential in treating epilepsy it is worth knowing the basic principles of these pro-
cesses. One of the major hallmarks of epilepsy is the presence of abnormal oscillatory events 
within neuronal networks in the form of recurrent interictal spikes and high frequency oscil-
lations within the epileptic zones of the patients’ brain [14]. These abnormal oscillations then 
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result in excessive synchronous firing of neurons causing an epileptic seizure with alteration 
in the patient’s behavior, motor activity or sensorium. Epilepsy can result from injury (either 
ischemic or traumatic) to cortical brain structures or genetic, inflammatory, structural and 
metabolic disturbances within the brain. The main components of the development of the 
abnormal oscillations within neuronal networks and epileptogenesis (seizure development) 
are (a) neuronal hyperexcitability—the ability of neurons to generate abnormal intrinsic burst 
discharges (b) a loss of GABA mediated interneuron neuronal inhibition that would nor-
mally prevent these discharges from spreading to adjacent neurons and (c) neuronal hyper-
synchrony in which excessive synaptic enhancement of neighboring neurons through the 
development of excitatory pathways allows these bursts to spread in a synchronous manner 
within a group of neurons [15]. Neuronal hyperexcitability can arise from abnormalities in 
excitatory or inhibitory neurotransmitter receptors resulting in a loss of the normal balance 
between neuronal excitation and inhibition. Of particular interest in epileptogenesis are the 
excitatory glutamatergic N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-
4-isoxazole propionate (AMPA) receptors [16]. Alterations in ion channel function as is seen 
in the channelopathy associated epilepsies such as Dravet syndrome also lead to neuronal 
hyperexcitability [17].
3. The endocannabinoid system and epilepsy
The endocannabinoid system comprises the two endogenous endocannabinoid recep-
tors (CB1R and CB2R) their two endogenously produced endocannabinoids; anandamide 
(N-arachidonyl-ethanolamide) and 2-AG (2-arachadonoylglycerol) which act as endogenous 
CBR ligands as well as the enzymes involved in endocannabinoid production and break-
down. Of the endocannabinoids produced in the human brain, 2-AG is produced in much 
higher concentrations and plays the most significant role in regulation of oscillatory networks 
[18]. For a full review of the endocannabinoid system please refer to this book’s introduction 
and the review article by Ligresti et al. [19] CB1R is one of the most abundant G protein-
coupled receptors (GPCR) within the mammalian brain and is expressed on the presynaptic 
axon terminal. In response to activation of the postsynaptic neuron, anandamide (a partial 
CB1R agonist) and 2-AG (a full CB1R agonist) are both produced within and released by the 
postsynaptic neuron. Activation of the presynaptic CB1R receptors by the endocannabinoids 
then results in a temporary suppression in voltage gated Ca2+ channels and activation of K+ 
channels resulting in suppression of further neurotransmitter release from the presynaptic 
neuron [20].
Although CB1R is one of the most abundantly expressed GPCRs in the brain, its expression 
is concentrated within certain groups of neurons. For example, in the hippocampus, CB1R 
expression is concentrated on the axon terminals of inhibitory GABAergic CA1 region inter-
neurons and Schaffer collaterals arising from CA3 pyramidal cells [22]. These interneurons 
play a key role in the formation and maintenance of normal oscillatory behavior in the hip-
pocampus essential for memory formation [18]. The effect of stimulation of CB1R is very 
localized within neuronal networks both from a spatial and temporal point of view. This 
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is achieved by the production of monoacylglycerol lipase (MAGL) by astrocytes and nerve 
terminals which breaks down 2-AG in the synaptic cleft. This temporal and spatial control 
allows for precise regulation of oscillations within neuronal networks by the endocannabi-
noid system [18].
During an epileptic seizure there is excessive glutamate release from presynaptic excitatory 
neurons. In rodent models of epilepsy this has been shown to cause increased production of 
both 2-AG and anandamide that in turn active CB1R on the glutamatergic axon terminals to 
decrease the release of further excessive glutamate. This prevents further neuronal hyperex-
citability which may play a role in terminating seizures. The increased anandamide is felt to 
play a role in preventing seizure induced excitatory neurotoxic effects [18, 21].
Temporal lobe epilepsy secondary to mesial temporal sclerosis (scarring of the hippocampi) is 
a common cause of epilepsy in adults that is often amenable to surgical resection of the mesial 
temporal structures. Pathological examination of surgically resected specimens has shown 
alterations in expression of CB1R of neurons within the hippocampi that provide insight 
into how disruption of the endocannabinoid system could predispose to epileptogenesis. In 
resected hippocampi there is a downregulation of CB1R expression on the axon terminals of 
excitatory (glutamatergic) neurons within the inner molecular layer of the dentate gyrus and 
an upregulation of CB1R expression on inhibitory (GABAergic) axon terminals within the 
dentate molecular layer [18]. These changes in CB1R expression result in both a loss of the 
normal inhibition of excessive glutamate release and increased suppression of GABAergic 
activity both of which result in increased neuronal hyperexcitability and subsequent seizure 
generation [22]. In patients with chronic epilepsy, there is also a decrease in the amount of 
anandamide and 2-AG released with excessive neuronal activation further contributing to a 
loss of the endocannabinoid mediated inhibition of excessive neuronal activation [18].
The growing body of evidence demonstrating the role the endocannabinoid system plays in 
the brains’ mechanisms in regulating neuronal network oscillations and preventing excessive 
neuronal hyperexcitability coupled with alterations in the endocannabinoid receptors seen in 
epileptogenic tissue make the endocannabinoid system an attractive therapeutic target in the 
treatment of epilepsy. Modulation of the endocannabinoid system would provide a potential 
novel anticonvulsant mechanism not provided by other anticonvulsant therapies.
4. Phytocannabinoids and epilepsy: mechanisms of action and 
preclinical studies
The phytocannabinoids are a class of cannabinoids that are produced by plants of the can-
nabis species. The phytocannabinoids are C
21
 aromatic compounds consisting of an aromatic 
isoprenyl terpenophenolic core and resorcinyl side chain. Based on the structure of the oxygen 
bond between the isoprenyl and resorcinyl moieties the phytocannabinoids can be placed into 
6 main families. Within each family, variations of the R-chain on the resorcinyl moiety differ-
entiate each individual cannabinoid [23]. To date, over 140 different phytocannabinoids have 
been identified in C. sativa. While there is a high degree of structural preservation among the 
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phytocannabinoids, they appear to display widely different effects on the mammalian central 
nervous system. The structural and stereochemical requirements for biological activity of the 
cannabinoids have been well established. Most biologically active cannabinoids (with a few 
exceptions) have a hydroxyl group on the C
1
 and an alkyl group on the C
3
 aromatic positions. 
As well, naturally occurring cannabinoids are biologically active in the trans (−) enantiomer 
[24]. Following the first isolation of the cannabinoids it did not take long for their anticonvul-
sant properties to be recognized [25]. Of the cannabinoids produced by the C. sativa the most 
comprehensively studied in the field of epilepsy are Δ9-tetrahydrocannabinol (Δ9-THC) and 
cannabidiol (CBD).
Initial research focused on the anticonvulsant effects of Δ9-THC and other CB1R agonists 
such as anandamide. Through their activation of CB1R, anandamide and the synthetic can-
nabinoid WIN 55,212-2 were able to block the production of postsynaptic neuronal spiking 
and excitatory post synaptic potential production. Both compounds were also able to sup-
press the production of abnormal burst activity in neurons placed in Mg
2
+ depleted solu-
tion. Depletion of Mg2+ in solution allows activation of NMDA receptors at normal resting 
potentials without the usual prerequisite neuronal depolarization. This effect was abolished 
when CB1R antagonists were added, suggesting that the effect was secondary to activation 
of CB1R by these agents [26]. Δ9-THC is a major phytocannabinoid in C. sativa. It is a high 
affinity partial agonist of both CB1R and CB2R that is competitive with both anandamide 
and 2-AG. The direct activation of CB1R by Δ9-THC is responsible for its psychoactive effects 
[19]. Numerous studies have assessed the anticonvulsant activity of Δ9-THC and its metabo-
lites with conflicting results. These studies showed that Δ9-THC and its metabolites showed 
both anticonvulsant and proconvulsant activity depending on the dosage, animal species and 
seizure model used. In Maximal Electroshock (MES) and Maximal Electroshock Threshold 
(MEST) mouse models which mimic generalized onset convulsive seizures both Δ9-THC and 
its metabolites showed anticonvulsant activity by blocking or increasing the latency to hind 
limb extensor seizures [27]. In other studies Δ9-THC was also shown to potentiate the effects 
of several anticonvulsants [28]. In models that showed an anticonvulsant effect of Δ9-THC, all 
three of its metabolites including 11-OH-Δ9-THC showed anticonvulsant effect. The anticon-
vulsant effect of 11-OH-Δ9-THC was more potent than its parent compound by almost 1 order 
of magnitude suggesting that much of the anticonvulsant activity attributed to Δ9-THC may 
in fact come from its metabolites [27].
In a rat model of electrically induced limbic seizures Δ9-THC increased the threshold of elec-
trically induced after discharges at the site of electrode implantation in the left subiculum. 
However, Δ9-THC increased the duration of cortically recorded after discharges in electrodes 
remote from the site of stimulation. This suggested that Δ9-THC may have both anticonvulsant 
and proconvulsant effects in focal onset epilepsies [27]. In the cobalt model of focal epilepsy 
in rats Δ9-THC increased the frequency of epileptic potentials at the site of the cobalt-induced 
lesion. This was not seen with Δ9-THC’s main metabolite 11-OH-Δ9-THC. Both Δ9-THC and 
11-OH-Δ9-THC seemed to increase generalized cortical excitation as seen by the production 
of brief intermittent cortically recorded after discharges [27]. Similar findings were seen in a 
rat model using iron to induce a seizure focus. While both Δ9-THC and 11-OH-Δ9-THC both 
caused increased cortical excitability, only Δ9-THC provoked clinical seizures. As well, the 
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dose of Δ9-THC required to induce seizures was much higher than that required to induce 
electrographic changes in keeping with cortical excitation [29]. In mice, Δ9-THC has also 
been shown to induce kindling of a second epileptic focus in response to both electroconvul-
sive therapy as well as pentylenetetrazol (PTZ) and picrotoxin induced seizures [30]. When 
administered to rabbits with a genetic mutation causing audiogenic seizures Δ9-THC caused 
signs of neurotoxicity but prevented seizures when the rabbits were stimulated with a sound 
stimulus above their normal seizure threshold range. Conversely, in another breed of rab-
bits, injection with Δ9-THC induced both neurotoxicity and behavioral seizures in a dosage 
dependent manner [31].
The results of these studies show that Δ9-THC and its metabolites display anticonvulsant 
activity in animal models using seizure models with rapidly evoked tonic discharges which 
mimics certain types of generalized onset seizures in humans. However, in models mimick-
ing focal onset seizures, Δ9-THC and its metabolites seem to display a proconvulsant effect. 
This is manifested by increasing the activity at the site of the focal lesion and increasing 
generalized cortical activity [27]. A proconvulsant effect is also seen in models mimicking 
genetic based generalized epilepsies and absence seizures. Δ9-THC and its metabolites seem 
to induce hypersynchrony with slowly propagating epileptic discharges [32]. While Δ9-THC 
showed some potential as an anticonvulsant agent the potential to increase seizure activity 
along with its neurotoxic and psychotropic side effect profile limited its potential benefit in 
patients with epilepsy.
CBD is a low affinity negative allosteric modulator of CB1R with no psychotropic side effects 
due to the fact it does not cause activation of CB1R. It modulates the influx of both Ca2+ and 
Na+ into neurons by binding to human T-type voltage gated Ca2+ channels, Melastatin and 
Vanilloid type Transient Receptor Potential membrane receptors (TRPM and TRPV) and volt-
age gated Na+ channels [19]. This decreases neuronal excitability in response to stimulation. 
CBD has also been shown to inhibit intrasynaptic re-uptake of adenosine as well as activation 
of neuronal Serotonin, Glycine and Vanilloid receptors [33, 34]. The anticonvulsant effect of 
CBD is felt to be independent of activation of the endogenous CBR pathways. While the exact 
mechanism of anticonvulsant activity of CBD remains uncertain it appears to have a poly-
pharmacological effect on modulating neuronal excitability.
In the Cobalt induced focal epilepsy rat model CBD had no effect on focal discharges at the 
lesion site but decreased the frequency of seizures. CBD also blocked the proconvulsant effects 
in of Δ9-THC [27, 35]. In the limbic seizure rat model CBD decreased the frequency, duration 
and amplitude of electrically induced after discharges at the site of stimulation in the left 
subiculum but did not prevent the spread of after discharges from the site of focal stimulation 
to distal electrodes. It had no apparent effect on generalized cortical excitability. This suggests 
that in focal models of epilepsy, CBD acts directly on the site of focal seizure onset [27].
Other animal studies continued to show the anticonvulsant effect of CBD in both transcor-
neal electroshock, drug induced and lesional epilepsies. This anticonvulsant effect was seen 
when a single intraperitoneal (i.p.) dose of CBD was administered alone but like Δ9-THC it 
also potentiated the effects of several anticonvulsant medications [33, 36, 37]. While CBD had 
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potent anticonvulsant effect against tonic seizures its effect against clonic seizures was minimal. 
Consroe et al. hypothesized that this effect was due to the fact that tonic seizures are spread rap-
idly throughout the brain from a focal lesion via post-tetanic stimulation. Unlike Δ9-THC, CBD 
suppressed tetanic potentiation in isolated bullfrog ganglia [27]. This coupled with the fact that 
CBD is effective in preventing 3-Mercaptoproprionic acid (3-MPA) induced seizures suggested 
that some of the anticonvulsant effect of CBD may result from its ability to increase production 
of GABA in presynaptic GABAergic neurons [36]. Unlike Δ9-THC, the brain concentrations of 
CBD correlated well with its anticonvulsant effect in several animal models. This suggests that 
the anticonvulsant effect of CBD is due to the parent compound and not its metabolites [27].
In summary, CBD was shown to display broad spectrum anticonvulsant activity in a wide 
range of animal models of epilepsy including generalized seizures caused by electroshock 
and GABA inhibiting drugs and focal seizures induced by placement of toxic metals on the 
cortex. It however had no effect on models of generalized absence seizures [38]. CBD also 
blocked kindling of a second epileptic focus [36]. Even at high doses it failed to cause any 
behavioral or cognitive side effects in test animals. This would suggest that CBD is a potent 
anticonvulsant with limited cognitive side effects, making it an attractive potential anticon-
vulsant in the pediatric population [33, 37].
4.1. Other cannabinoids and terpenes
In addition, Δ9-THC and CBD several other cannabinoids have been evaluated for the poten-
tial anticonvulsant activity. These include ∆9-tetrahydrocannibivarin (∆9-THCV) and can-
nabidivarin (CBDV) which have been shown to have anticonvulsant effects. ∆9-THCV is a 
non-psychoactive cannabinoid that acts as a CB1R antagonist. In a Mg2+ depleted solution ∆9-
THCV decreased the amplitude and duration of abnormal neuronal burst activity. ∆9-THCV 
potentiated the effects on neuronal bursting of both phenobarbital and valproic acid. In a PTZ 
rat model ∆9-THCV did not decrease the severity or duration of seizures or seizure mortality. 
However significantly fewer rats exposed to PTZ that were treated with ∆9-THCV displayed 
seizures compared to those that were given PTZ alone [39]. Like CBD, CBDV is believed to 
exert its effects via CB1R independent mechanisms and has limited neurotoxicity [40]. CBDV 
has been shown to decrease the amplitude and duration of abnormal bursting in mouse and 
rat hippocampal slices in in both Mg2+ depleted solution and solution to which 4-aminopyri-
dine (4-AP) has been added. CBDV also significantly decreased the number of seizures seen in 
in vitro MES and audiogenic seizure models in mice and PTZ induced seizures in rats. Unlike 
CBD, CBDV also prolonged the latency of seizure induction in a dose dependent manner. 
Administration of CBDV had no effect on motor performance in mice regardless of the ode 
administered [41]. The terpenes, which are another class of compounds found in cannabis, 
also possess a wide range of pharmacological activity on the mammalian nervous system at 
very low concentrations. Individually, these terpenes have not been assessed in patients with 
epilepsy [42, 43].
The combinatorial effect of the chemical components of cannabis has been postulated wherein 
cannabis whole plant extracts may benefit from ‘entourage’ effects to yield greater effectiveness 
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than treatment with a purified cannabinoid [42, 44]. This is supported by preclinical studies. 
In the in vitro oxotremorine-M mouse model of epilepsy, excessive neuronal bursting activity 
can be suppressed with ∆9-THC, but not CBD, while a standardized cannabis extract contain-
ing both ∆9-THC and CBD can abolish the abnormal bursting activity faster than purified 
∆9-THC alone [45]. In another study, both purified ∆9-THC and CBD can increase intracellular 
Ca2+ in rat hippocampal neuronal and glial cells. This effect is compounded when the two 
compounds are mixed together, with the greatest effect occurring with whole plant extract 
containing both ∆9-THC and CBD [46]. These preclinical data support the hypothesis that the 
‘entourage’ effects between the various cannabinoids provide therapeutic benefit of cannabis 
whole plant extract, benefit that exceeds the activity of a single purified cannabinoid. This 
remains to be demonstrated in the human clinical context.
5. Early clinical experience with cannabis for the treatment of 
epilepsy
The use of cannabis as a treatment for a variety of ailments in eastern and Mediterranean 
cultures over the last several millennium has been well documented [47]. The first description 
of the use of cannabis to treat seizures came from Dr. W. O’Shaugnessy who while working 
in India reported its successful use to treat seizures in an infant [48]. Following this, cannabis 
extracts became widely used throughout Europe and North America as an accepted treatment 
for epilepsy [49]. Following prohibition and with the introduction of other anticonvulsants, 
cannabis fell out of use as a treatment for epilepsy in western cultures.
During the mid-twentieth century, several reports on the effect of recreational cannabis con-
sumption surfaced with contrasting effects. Several case reports described patients having 
decreased seizure frequency following the consumption of cannabis [50]. Cannabis consump-
tion was also shown to be protective against first unprovoked seizures. In adult males who 
smoked cannabis in the last 90 days, the odds of having a first unprovoked seizure was 0.38 
compared to adult males who never consumed cannabis [51]. Conversely, a patient with a 
history of epilepsy who had been seizure free for several months on medication was reported 
to have had an exacerbation of seizures following the consumption of cannabis [52].
In 1978, Mechoulam et al. reported their double blinded placebo-controlled study of CBD 
used as an add-on therapy in patients with refractory focal onset seizures. Of the four patients 
who took CBD two were seizure free for the 3 months of the study while another had partial 
improvement. None of the five patients who took placebo had any improvement in their sei-
zures [53]. Cunha et al. reported the results of their study investigating the potential of CBD in 
patients with refractory temporal lobe epilepsy. In the first phase of the study, healthy adult 
volunteers were randomized to receive either placebo or CBD at 3 mg/kg/day for 30 days. Of 8 
volunteers receiving CBD, 2 reported somnolence otherwise no adverse effects were reported. 
In the second phase, 15 adult patients with drug-resistant temporal lobe epilepsy were ran-
domized to receive either placebo or CBD (up to 300 mg/day) for a period of 18 weeks in a 
double-blinded manner. Four of 8 patients dosed with CBD had complete improvement while 
three had partial improvement. No adverse effects were noted in patients given CBD [54].
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Two further studies showed no significant difference in seizure reduction with the addition 
of CBD as an adjunctive therapy. However, in one study patients were given CBD at a dose of 
300 mg/day and their plasma CBD levels were maintained at 20–30 ng/ml. Subsequently one 
participant who had no difference in their seizure frequency was placed on CBD at a higher 
dose of up to 1200 mg/day. CBD plasma levels were higher averaging 150 ng/ml. This patient 
had a significant decrease in their seizure frequency suggesting that higher doses of CBD (and 
higher plasma levels) were required for seizure control [55].
6. Recent clinical trials and experience
In recent years there has been a public perception that cannabis is a potent, natural, and safe 
alternative therapy for epilepsy. This has driven the demand for and use of cannabis and its 
derived products to treat epilepsy especially in those patients whose seizures are medically 
intractable. Coupled with the media exposure showing examples of the apparent miraculous 
effects of CBD oil in select epileptic patients, treating physicians have struggled to balance the 
patient demand for cannabis products and the need for studies to determine their, efficacy, 
dosing, side-effect profile, and indication. To that end, there have been multiple studies, pre-
dominantly in children, looking into these clinical questions. Unfortunately, the overwhelm-
ing majority of these studies have been retrospective, unblinded, and uncontrolled resulting 
in their being hampered by various forms of bias and potential placebo effect. Despite the 
plethora of published research on this topic, questions still remain on the use of cannabis in 
epilepsy.
In this section, we will review the limitations of the studies, the studies using artisanal and 
CBD enriched cannabis herbal extracts (CHE), the studies using highly purified pharmaceuti-
cal grade CBD, and a meta-analysis of the CBD studies.
6.1. Limitations of the studies
The widespread use of cannabis and the effect of bias are highlighted in various published 
surveys. McLachlan performed a survey in London, Ontario, Canada, in which more than 60% 
of patients declared that cannabis was effective for their seizures and stress levels [56]. Ladina 
et al. reported a case series of 18 patients who all found medicinal cannabis very helpful for 
seizure control and improvement of mood disorder [57]. By contrast, Press had reported a 
significant discrepancy in reported responder rate between preexisting Colorado residents 
and those who moved to Colorado to obtain cannabis to treat their child’s epilepsy (22 vs. 
47%) suggesting there is a significant perception bias among these children’s caregivers as to 
the therapeutic benefits of cannabis [58]. Physician bias may also play a role as a recent survey 
by Mathern showed contrasting opinions about CBD between neurologists and the general 
public. In his study, a minority of epileptologists and general neurologists said that there 
were sufficient data safety (34%) and efficacy data (28%) and only 48% would advise using 
medical cannabis and only in severe cases of epilepsy. Conversely, nearly all patients and the 
general public responded that there was sufficient safety (96%) and efficacy (95%) data, and 
98% would recommend cannabis in cases with severe epilepsy [59].
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Given the present approved indications for medical coverage, the high cost of pharmaceutical 
grade CBD products, and the illegal status of cannabis in some countries and US states, the 
overwhelming majority of patients will at this time be using CBD oil extracts or artisanal 
products. In many jurisdictions these products are unregulated and therefore their content 
and consistency are uncertain and can vary. In Australia, where medical use of cannabis is 
highly restricted, Suraev reported that in parents treating their children with “illicit” cannabis 
extracts, the majority of extract samples used by the families contained low concentrations 
of cannabidiol, while Δ9-THC was present in nearly every sample [60]. These findings high-
lighted the profound variation in the illicit cannabis extracts being used. Studies examining 
the use of artisanal and CBD oil extracts therefore could have had uncertain and inconsistent 
amounts of cannabinoids. This inconsistency in combination the inherent problems of ret-
rospective studies, make the findings of these studies questionable; moreover, none of pub-
lished studies included serum CBD levels.
To date, there are few prospective, double blind, placebo-controlled studies which all only 
examined the use of the highly purified, pharmaceutical grade CBD (Epidiolex). None 
involved artisanal CBD or the CBD oil extracts.
6.2. The artisanal and CBD oil extracts
While keeping the limitations of the studies examining artisanal and CBD oil extracts in epi-
lepsy in mind, most of these studies did find that CBD oil extracts are effective in reducing 
seizures and improving quality of life.
Tzadok reported out of 74 children being treated with a 20% CBD and 1% Δ9-THC CHE, 89% 
reported reduction in seizure frequency with only 43% of patients having a >50% reduction in 
seizures. Five patients reported aggravation of seizures leading to withdrawal from the study. 
Improvement in behavior and alertness, language, communication, motor skills and sleep 
were noted. Adverse reactions included somnolence, fatigue, gastrointestinal disturbances 
and irritability leading to withdrawal of cannabis use in five patients. The CBD dosing ranged 
from 1 to 20 mg/kg/day with 83% taking <10 mg/kg/day [61].
Similarly, Porcari retrospectively studied the efficacy of artisanal CBD preparations in chil-
dren with epilepsy. The study also included a subgroup comparison to determine if the 
addition of clobazam was related to any beneficial effects of CBD. Overall, the addition of 
CBD resulted in 39% of patients having a >50% reduction in seizures, with 10% becoming 
seizure-free. The difference in effect between CBD alone and CBD with clobazam was not 
statistically significant. Increased alertness and improved verbal interactions were reported 
in 14% of patients in the CBD group and 8% of patients in the CBD and clobazam group. The 
average dose of CBD was 2.9 mg/kg/day in the CBD group and 5.8 mg/kg/day in the CBD and 
clobazam group [62].
McCoy et al. performed a prospective open label study using a 2:100 Δ9-THC:CBD CHE in 
20 children with Dravet syndrome. The dose of CBD ranged from 7 to 16 mg/kg/day (mean 
13.3 mg CBD/kg/day). They reported that during the 20-week intervention period the median 
monthly reduction in motor seizures was 70.6%. The CHE also resulted in improvements 
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in quality of life measures and spike index on electroencephalogram (EEG). Adverse events 
during the titration period included somnolence, anorexia and diarrhea [63].
The Cannabinoid Research Initiative of Saskatchewan is currently conducting a Canadian, mul-
ticenter, prospective, open-label, dose-escalation phase 1 trial entitled Cannabidiol in Children 
with Refractory Epileptic Encephalopathy (CARE-E). The source of the CBD oil is consistent 
with a single batch of 1:20 Δ9-THC:CBD CHE used for all study participants. Concentrations 
of the cannabinoids in the CHE were confirmed through Health Canada Quality Assurance 
and Good Manufacturing Practices (GMP) certification [64]. Preliminary data showed that all 
6 participants had improvements in seizure frequency, Quality of Life in Childhood Epilepsy 
(QOLCE) and EEG rating scores—with three participants showing continued improvements in 
these measures after the oil extract was discontinued. In addition, serum CBD levels suggested 
linear dose independent pharmacokinetics in all but one participant. In most participants, serum 
Δ9-THC concentrations remained lower than what would be expected to cause intoxication even 
at the maximum dose of oil extract. None of the participants displayed any evidence of Δ9-THC 
intoxication clinically throughout the study. Preliminary data suggests that an effective and well-
tolerated CBD initial target dose of 5–6 mg/kg/day is effective and well tolerated when a 1:20 Δ9-
THC:CBD CHE is used. In addition, the serum concentration of CBD follows dose-independent 
linear pharmacokinetics for most participants, although non-linear pharmacokinetics might 
occur but requires confirmation. Continued improvement in seizure frequency and QOLCE fol-
lowing the discontinuation of CHE suggest a possible enduring anticonvulsant effect [65].
6.3. The highly purified, pharmaceutical grade CBD products
With the production of a highly purified, pharmaceutical grade CBD (Epidiolex), studies 
could now be performed with a CBD source of greater reliability. Although potential bias 
remained, better clinical studies had been performed.
Devinksy published an open label trial in patients aged 1–30 with severe, intractable, child-
hood-onset, drugs resistant epilepsy. All patients were receiving their regular anti-epileptic 
drugs. Patients were given CBD at 2–5 mg/kg/day, titrated over a period of 2 weeks till intol-
erance or to a maximum dose of 25 mg/kg to 50 mg/kg/day. The main objective of the study 
was to establish safety and tolerability of CBD and the primary end point was the median 
percentage in the mean monthly frequency of motor seizures at 12 weeks. This study included 
mainly patients with Dravet and Lennox-Gastaut syndromes. One hundred and sixty-two 
patients were enrolled. A significant high rate of adverse events was reported in 128 patients 
(79%). The most common were somnolence (n = 41 [25%]), decreased appetite (n = 31 [19%]), 
diarrhea (n = 31 [19%]) and fatigue (n = 21 [13%]). This high rate of side effects (many of 
which were seen during the titration period) suggests that too rapid a titration rate may pre-
dispose toward side effects. The median monthly frequency of motor seizures was 30·0 (IQR 
11·0–96·0) at baseline and 15·8 (5·6–57·6) at 12 weeks of treatment. The median reduction in 
monthly motor seizures was 36·5% (IQR 0–64·7) [66].
From this same cohort, Rosenberg et al. reported that caregivers of 48 patients indicated 
an 8.2–9.9-point improvement in overall patient QOLCE (p < 0.001) following 12 weeks of 
CBD. Subscores with improvement included energy/fatigue, memory, control/helplessness, 
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other cognitive functions, social interactions, behavior, and global quality of life (QOL). 
Interestingly, these differences were not correlated to changes in seizure frequency or adverse 
events. The results suggest that CBD may have beneficial effects on patient QOL, distinct from 
its seizure reducing effects [67].
Devinsky et al. later performed a double blind, placebo-controlled trial in patients with 
Dravet syndrome including 120 children and young adults using Epidiolex with a CBD dos-
age of 20 mg/kg/day. The median frequency of convulsive seizures per month decreased from 
12.4 (baseline) to 5.9 with CBD, as compared with a decrease from 14.9 (baseline) to 14.1 with 
placebo (adjusted median difference between cannabidiol vs. placebo was −22.8% points [CI], 
−41.1 to −5.4; p = 0.01). The percentage of patients who had at least a 50% reduction in con-
vulsive seizure frequency was 43% with cannabidiol and 27% with placebo (odds ratio, 2.00; 
95% CI, 0.93–4.30; p = 0.08). This study shows an overall benefit of CBD over placebo but also 
a large placebo effect in the control group [68].
Another trial that assessed the efficacy of Epidiolex in reducing atonic seizures in patients with 
Lennox-Gastaut syndrome. In this double blind, placebo-controlled trial, a total of 225 patients 
were enrolled, 76 patients were assigned to a treatment group (20 mg/kg/day CBD) and 76 to 
the placebo group. The median percent reduction from baseline in monthly atonic seizure fre-
quency during the treatment period was 41.9% in the treatment group vs. 21.8% in the placebo 
group. As with the other studies assessing Epidiolex, the most common adverse events among 
the patients in the treatment groups were somnolence, decreased appetite, and diarrhea [69].
A recent systematic review assessed the safety and efficacy of pharmaceutical grade CBD in 
pediatric onset drug resistant epilepsy with outcome measures including 50% seizure reduc-
tion, complete seizure freedom, improved QOL. A total of 36 studies were identified includ-
ing 6 randomized controlled trials and 30 observational studies. Overall CBD at a dose of 
20 mg/kg/day was more effective than placebo in reducing seizure frequency by 50% (Relative 
Risk 1.74: 1.24–2.43). For one patient to achieve a 50% reduction in seizures the number of 
patient needed to treat was 8. In pooled data of 17 of the observational studies CBD at 20 mg/
kg/day resulted in 48.5% of patients achieving a 50% reduction in seizures (95% CI: 39.0–58.1%) 
while pooled data from 14 observational studies showed 8.5% of patients became seizure free 
(95% CI: 3.8–14.5%). Quality of life improved in 55.8% of patients (95% CI: 40.5–70.6%) while 
serious adverse events related to treatment with CBD was very low at 2.2% of patients (95% 
CI: 0.0–7.9%). From this data, the authors concluded that pharmaceutical grade CBD may 
reduce seizure frequency but other randomized controlled trials examining a more diverse 
group of epilepsy syndromes and other cannabinoids was needed [70].
To date, the evidence to support the use of cannabis in adults is minimal. STAR 1 is a phase 
2A, randomized, double blind, placebo-controlled study that evaluated the safety and efficacy 
of synthetic transdermal CBD in adult patients with focal epilepsy. In this study 174 patients 
were randomized to receive either 195 mg CBD, 390 mg CBD or placebo via a transdermal 
patch. Patients who completed the 12-week study were able to continue into the 24-month 
open-label extension STAR 2 study (n = 171). In as of yet published data from these trials 
there was an increase in efficacy of transdermal CBD over 18 months. Median percentage 
change in seizure rates was −25% at 3 months, −40% at 6 months, −48% at 9 months, −52% at 
Recent Advances in Cannabinoid Research212
12 months, −57% at 15 months and −55% at 18 months. The transdermal patch was well toler-
ated. Serious adverse events were as follows: seizures (n = 2) and increased anxiety (n = 1); one 
death was reported after the 15 month visit. In addition, no significant elevations in alanine 
aminotransferase and aspartate aminotransferase levels >3 times upper limit of normal were 
seen [71].
In comparing cannabis derived treatments to standard therapies, it is worthwhile to note 
that the STICLO group examining the effects of stiripentol in Dravet patients in a double 
blind randomized placebo controlled study showed that 15 (71%) patients had >50% seizure 
reduction (including nine free of clonic or tonic-clonic seizures) compared to only one (5%) on 
placebo (none were seizure free; stiripentol 95% CI 52.1–90.7 vs. placebo 0–14.6). Stiripentol’s 
responder rate is therefore suggested to be superior to Epidiolex with a far lower placebo 
responder rate [72]. Similarly, in a double-blind, randomized, placebo-controlled trial of the 
anti-epileptic drug rufinamide in patients with Lennox-Gastaut syndrome, the median per-
centage reduction in total seizure frequency was greater in the rufinamide therapy group 
than in the placebo group (32.7 vs. 11.7%, p = 0.0015). There was also a difference (p < 0.0001) 
in tonic-atonic (“drop attack”) seizure frequency with rufinamide (42.5% median percentage 
reduction) vs. placebo (1.4% increase). These findings are comparable with the results with 
Epidiolex. One also has to keep in mind that the median reduction of atonic seizures in the 
placebo group was markedly higher with the Epidiolex study suggesting potential bias [73].
Of note, the results from the study by McCoy et al. and the preliminary data from CARE-E study 
showed a much higher responder rate than those with pharmaceutical grade CBD. This appar-
ent superiority of a CHE containing Δ9-THC would be in keeping with the proposed entourage 
effect in which the various cannabinoids can act synergistically with one another [42, 44].
7. Conclusion
The cannabinoids found in cannabis appear to offer a unique pharmacological mode of action 
in the treatment of epilepsy. This, combined with the apparent low risk of serious side effects, 
makes cannabis and an attractive potential option for patients with treatment resistant epilepsy.
Currently, there is a large public perception that cannabis products are superior to and safer 
than conventional anti-epileptic medications especially in treating patients with Dravet syn-
drome and other pediatric onset epileptic encephalopathies. Based on interpretation of the 
available data, the authors feel that cannabis based therapies show promise in the treatment 
of children with treatment resistant epilepsies. While the studies to date assessing cannabis 
based therapies for the treatment of epilepsy have been encouraging, they should be inter-
preted with caution. At this time, the long-term adverse effects, the indicated epilepsy and 
seizure types suitable for treatment with cannabis, the dosing of CBD and other cannabinoids, 
remain unknown. Also, there is minimal data regarding the pharmacokinetics of the canna-
binoids especially in children and when used in patients with multiple concomitant medica-
tions. Moreover, the existing studies are limited with the majority of them being retrospective 
and subject to bias, possible placebo effect, and other limitations.
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As such, further studies assessing the safety and efficacy of cannabis based therapies in 
both adults and children are urgently needed. The authors recommend that these stud-
ies start with well-designed dose finding studies that include age stratified pharmacoki-
netic analysis followed by larger scale clinical trials. When faced with physicians that are 
reluctant to authorize cannabis based products due to a lack of high quality safety and 
efficacy data, parents who are desperate to help their children are then forced to turn to 
unregulated suppliers of cannabis. This puts their children at risk of harm and themselves 
in legal jeopardy.
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